PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.08M | -4.39M | 746.90K | -7.42M | -8.36M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.48M | 4.08M | -1.51M | 6.31M | 7.32M |
| Change in Net Operating Assets | -181.30K | -1.08M | -20.80K | 129.70K | -954.80K |
| Cash from Operations | -780.90K | -1.39M | -786.80K | -979.50K | -1.99M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 5.00M | -3.00M | -- |
| Cash from Investing | -- | 0.00 | 5.00M | -3.00M | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 1.05M | -- | -- |
| Repurchase of Common Stock | -- | 0.00 | -401.60K | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 6.27M | -- |
| Repurchase of Preferred Stock | -- | -86.40K | -- | -- | -- |
| Total Dividends Paid | -83.40K | -83.40K | -101.40K | -61.30K | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.40K | -169.80K | 543.80K | 6.21M | -- |
| Foreign Exchange rate Adjustments | -600.00 | 700.00 | 2.60K | -400.00 | 100.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -864.90K | -1.56M | 4.76M | 2.23M | -1.99M |